RECOVERY / SINGLE
ARA-290
10MGThis content is intended for educational and research reference only and does not constitute medical advice, diagnosis, or treatment. Experimental compounds are for research use only and are not for human consumption. Always consult qualified healthcare providers before starting any therapy.
Research Overview
A non-erythropoietic EPO derivative studied in neuropathy and tissue-protection research.
Available Strengths
- 10MG (RA10)
Research Protocol
Reference two-phase schedule
| Period | Dose | U-100 units | Volume |
|---|---|---|---|
| Week 1 | 2 mg | 25 | 0.25 mL |
| Weeks 2–8+ | 4 mg | 50 | 0.5 mL |
Reconstitution
≈8.0 mg/mL once reconstituted
- Draw 1.25 mL of bacteriostatic water per 10 mg vial.
- Inject slowly along the vial wall; swirl gently until dissolved.
Research context
Reported to selectively activate the innate repair receptor (an EPOR/CD131 heterodimer), promoting anti-inflammatory and tissue-protective effects without stimulating red-blood-cell production.
Storage
2–8°C refrigerated, or −20°C frozen, up to 3 years. 2–8°C, use within 28 days; do not freeze the liquid.
Research Notes
- For educational and research reference only. Not medical advice and not intended for unsupervised human use.
- DXBTides' 10 mg vial has no dedicated source page; the source's own 16 mg vial page was used, holding its 8.0 mg/mL concentration constant and scaling reconstitution water down to 1.25 mL for this smaller vial — the daily mg dose and resulting injection volumes are unchanged from the source's own figures. Cited trials found no additional benefit at doses above 4 mg/day.
References
Source reference: PeptideDosages.com · 2026-08-18 · Mathematically derived for this strength from the compound's verified reference data